The FDA has “finalized” guidelines allowing drug companies to promote drugs for unapproved (”off-label”) uses. The guidelines will allow companies to distribute peer-reviewed scientific literature discussing off-label uses.
The FDA has “finalized” guidelines allowing drug companies to promote drugs for unapproved (”off-label”) uses. The guidelines will allow companies to distribute peer-reviewed scientific literature discussing off-label uses.
